|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DNAJC7 |
Gene summary for DNAJC7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DNAJC7 | Gene ID | 7266 |
| Gene name | DnaJ heat shock protein family (Hsp40) member C7 | |
| Gene Alias | DJ11 | |
| Cytomap | 17q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0006457 | UniProtAcc | Q99615 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7266 | DNAJC7 | LZE2T | Human | Esophagus | ESCC | 7.64e-05 | 6.40e-01 | 0.082 |
| 7266 | DNAJC7 | LZE4T | Human | Esophagus | ESCC | 3.24e-11 | 6.00e-01 | 0.0811 |
| 7266 | DNAJC7 | LZE5T | Human | Esophagus | ESCC | 6.14e-04 | 1.58e-01 | 0.0514 |
| 7266 | DNAJC7 | LZE7T | Human | Esophagus | ESCC | 1.30e-07 | 5.34e-01 | 0.0667 |
| 7266 | DNAJC7 | LZE8T | Human | Esophagus | ESCC | 1.01e-08 | 3.30e-01 | 0.067 |
| 7266 | DNAJC7 | LZE22D1 | Human | Esophagus | HGIN | 1.75e-02 | 4.19e-02 | 0.0595 |
| 7266 | DNAJC7 | LZE24T | Human | Esophagus | ESCC | 5.76e-20 | 5.64e-01 | 0.0596 |
| 7266 | DNAJC7 | LZE21T | Human | Esophagus | ESCC | 2.98e-05 | 5.15e-01 | 0.0655 |
| 7266 | DNAJC7 | LZE6T | Human | Esophagus | ESCC | 1.02e-07 | 3.52e-01 | 0.0845 |
| 7266 | DNAJC7 | P1T-E | Human | Esophagus | ESCC | 8.60e-09 | 6.11e-01 | 0.0875 |
| 7266 | DNAJC7 | P2T-E | Human | Esophagus | ESCC | 2.37e-43 | 7.99e-01 | 0.1177 |
| 7266 | DNAJC7 | P4T-E | Human | Esophagus | ESCC | 4.49e-40 | 1.08e+00 | 0.1323 |
| 7266 | DNAJC7 | P5T-E | Human | Esophagus | ESCC | 6.71e-50 | 1.06e+00 | 0.1327 |
| 7266 | DNAJC7 | P8T-E | Human | Esophagus | ESCC | 6.04e-32 | 6.40e-01 | 0.0889 |
| 7266 | DNAJC7 | P9T-E | Human | Esophagus | ESCC | 3.32e-27 | 5.11e-01 | 0.1131 |
| 7266 | DNAJC7 | P10T-E | Human | Esophagus | ESCC | 1.95e-31 | 6.46e-01 | 0.116 |
| 7266 | DNAJC7 | P11T-E | Human | Esophagus | ESCC | 4.01e-21 | 1.07e+00 | 0.1426 |
| 7266 | DNAJC7 | P12T-E | Human | Esophagus | ESCC | 1.17e-32 | 7.57e-01 | 0.1122 |
| 7266 | DNAJC7 | P15T-E | Human | Esophagus | ESCC | 4.74e-30 | 8.42e-01 | 0.1149 |
| 7266 | DNAJC7 | P16T-E | Human | Esophagus | ESCC | 5.12e-36 | 7.36e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000645720 | Esophagus | HGIN | protein folding | 75/2587 | 212/18723 | 1.61e-15 | 3.86e-13 | 75 |
| GO:003460520 | Esophagus | HGIN | cellular response to heat | 30/2587 | 69/18723 | 1.78e-09 | 1.35e-07 | 30 |
| GO:006107720 | Esophagus | HGIN | chaperone-mediated protein folding | 27/2587 | 67/18723 | 7.99e-08 | 4.20e-06 | 27 |
| GO:000645820 | Esophagus | HGIN | 'de novo' protein folding | 19/2587 | 43/18723 | 1.25e-06 | 4.83e-05 | 19 |
| GO:000940819 | Esophagus | HGIN | response to heat | 34/2587 | 110/18723 | 2.94e-06 | 1.01e-04 | 34 |
| GO:005108420 | Esophagus | HGIN | 'de novo' posttranslational protein folding | 16/2587 | 39/18723 | 2.70e-05 | 7.03e-04 | 16 |
| GO:005108520 | Esophagus | HGIN | chaperone cofactor-dependent protein refolding | 14/2587 | 34/18723 | 8.15e-05 | 1.80e-03 | 14 |
| GO:000926618 | Esophagus | HGIN | response to temperature stimulus | 42/2587 | 178/18723 | 2.91e-04 | 4.98e-03 | 42 |
| GO:19000344 | Esophagus | HGIN | regulation of cellular response to heat | 7/2587 | 17/18723 | 5.21e-03 | 4.30e-02 | 7 |
| GO:0006457110 | Esophagus | ESCC | protein folding | 163/8552 | 212/18723 | 1.13e-20 | 1.74e-18 | 163 |
| GO:0061077110 | Esophagus | ESCC | chaperone-mediated protein folding | 56/8552 | 67/18723 | 1.52e-10 | 4.36e-09 | 56 |
| GO:0009408110 | Esophagus | ESCC | response to heat | 77/8552 | 110/18723 | 2.01e-07 | 3.11e-06 | 77 |
| GO:0006458110 | Esophagus | ESCC | 'de novo' protein folding | 36/8552 | 43/18723 | 2.90e-07 | 4.20e-06 | 36 |
| GO:0034605111 | Esophagus | ESCC | cellular response to heat | 52/8552 | 69/18723 | 4.87e-07 | 6.53e-06 | 52 |
| GO:0051084110 | Esophagus | ESCC | 'de novo' posttranslational protein folding | 32/8552 | 39/18723 | 3.27e-06 | 3.65e-05 | 32 |
| GO:0051085110 | Esophagus | ESCC | chaperone cofactor-dependent protein refolding | 27/8552 | 34/18723 | 6.01e-05 | 4.62e-04 | 27 |
| GO:000926619 | Esophagus | ESCC | response to temperature stimulus | 106/8552 | 178/18723 | 1.30e-04 | 8.84e-04 | 106 |
| GO:190003412 | Esophagus | ESCC | regulation of cellular response to heat | 13/8552 | 17/18723 | 1.00e-02 | 3.42e-02 | 13 |
| GO:00064577 | Liver | Cirrhotic | protein folding | 114/4634 | 212/18723 | 9.23e-20 | 2.31e-17 | 114 |
| GO:00610777 | Liver | Cirrhotic | chaperone-mediated protein folding | 40/4634 | 67/18723 | 1.24e-09 | 5.43e-08 | 40 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DNAJC7 | SNV | Missense_Mutation | c.1384N>A | p.Asp462Asn | p.D462N | Q99615 | protein_coding | tolerated(0.09) | possibly_damaging(0.58) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DNAJC7 | SNV | Missense_Mutation | c.1120C>A | p.Leu374Met | p.L374M | Q99615 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AN-A0AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DNAJC7 | SNV | Missense_Mutation | c.1205N>A | p.Arg402Gln | p.R402Q | Q99615 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD | |
| DNAJC7 | SNV | Missense_Mutation | c.718G>A | p.Ala240Thr | p.A240T | Q99615 | protein_coding | tolerated(0.05) | possibly_damaging(0.515) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
| DNAJC7 | SNV | Missense_Mutation | novel | c.320N>C | p.Leu107Pro | p.L107P | Q99615 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | SD | |
| DNAJC7 | insertion | Frame_Shift_Ins | novel | c.1234_1235insAGGAGACT | p.Arg412GlnfsTer45 | p.R412Qfs*45 | Q99615 | protein_coding | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| DNAJC7 | insertion | Frame_Shift_Ins | novel | c.1232_1233insGCATGGTGGTGCATGCCTGTGGTCCAAGCTAC | p.Asp411GlufsTer54 | p.D411Efs*54 | Q99615 | protein_coding | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| DNAJC7 | insertion | Nonsense_Mutation | novel | c.1240_1241insTGAGCTGAGATCGCACCACTGCACTCCAGCCTGGCGACAGAG | p.Ser414delinsMetSerTerAspArgThrThrAlaLeuGlnProGlyAspArgGly | p.S414delinsMS*DRTTALQPGDRG | Q99615 | protein_coding | TCGA-BH-A0HW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| DNAJC7 | SNV | Missense_Mutation | rs369947605 | c.1409N>G | p.Lys470Arg | p.K470R | Q99615 | protein_coding | tolerated(0.86) | benign(0) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| DNAJC7 | SNV | Missense_Mutation | c.1366G>A | p.Glu456Lys | p.E456K | Q99615 | protein_coding | tolerated(0.33) | benign(0.017) | TCGA-EX-A69L-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |